These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30564993)

  • 1. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.
    Detrez I; Schops G; Lefrère J; Tops S; Van Assche G; Vermeire S; Van Moerkercke W; Ferrante M; Gils A
    AAPS J; 2018 Dec; 21(1):10. PubMed ID: 30564993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.
    Bian S; Van den Berghe N; Vandersmissen L; Tops S; Vermeire S; Ferrante M; Gils A; Thomas D
    J Pharm Biomed Anal; 2020 Jun; 185():113224. PubMed ID: 32151929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Samaan MA; Cunningham G; Tamilarasan AG; Beltran L; Pavlidis P; Ray S; Mawdsley J; Anderson SH; Sanderson JD; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):292-302. PubMed ID: 32506695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.
    Kneepkens EL; Pouw MF; Wolbink GJ; Schaap T; Nurmohamed MT; de Vries A; Rispens T; Bloem K
    Br J Clin Pharmacol; 2017 Nov; 83(11):2474-2484. PubMed ID: 28791718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
    Philip G; Cornillie F; Adedokun JO; Melsheimer R; Rutgeerts P; Colombel JF; Marano C
    J Crohns Colitis; 2019 Sep; 13(10):1257-1264. PubMed ID: 30847474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
    Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
    Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
    [No Abstract]   [Full Text] [Related]  

  • 13. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical and clinical validation of an LC-MS/MS method for carbamazepine, lamotrigine and levetiracetam in dried blood spots.
    Besten-Bertholee DD; Wegner I; Touw DJ; Ter Horst PGJ
    Eur J Hosp Pharm; 2024 Aug; 31(5):450-454. PubMed ID: 36894298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.
    Boland K; Greener T; Kabakchiev B; Stempak J; Tessolini J; Li R; Soriano J; Croitoru K; Nguyen G; Steinhart AH; Weizman AV; Silverberg MS
    Inflamm Bowel Dis; 2020 Apr; 26(5):766-773. PubMed ID: 31676891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra
    Bloem K; Schaap T; Boshuizen R; Kneepkens EL; Wolbink GJ; Vries A; Rispens T
    Bioanalysis; 2018 Jun; 10(11):815-823. PubMed ID: 29863412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dried blood spot analysis of gabapentin as a valid alternative for serum: a bridging study.
    Sadones N; Van Bever E; Van Bortel L; Lambert WE; Stove CP
    J Pharm Biomed Anal; 2017 Jan; 132():72-76. PubMed ID: 27697572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection.
    Hahn RZ; Arnhold PC; Andriguetti NB; Schneider A; Klück HM; Dos Reis SL; Bastiani MF; Kael I; da Silva ACC; Schwartsmann G; Antunes MV; Linden R
    J Pharm Biomed Anal; 2018 Feb; 150():51-58. PubMed ID: 29216585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of atenolol in dried blood spot samples by LC-HRMS: a potential method for assessing medication adherence.
    Lawson G; Cocks E; Tanna S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 897():72-9. PubMed ID: 22552005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.